Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits.
Exosome Companies and Exosome Therapies
In this article:
- What are Exosomes?
- Where are Exosomes Found?
- Exosome Therapeutics in Regenerative Medicine
- Exosome Market Momentum
- Companies Commercializing Exosome Technologies
What are Exosomes?
Exosomes play an important role in various cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.
Exosomes are commonly found in blood, urine, and saliva, among other fluids. Exosomes are also present in other body fluids, such as synovial fluid, amniotic fluid, semen, vaginal fluid, breast milk, and more.
It has been long known that stem cells have the potential to exert therapeutic effects, but it has only been recently recognized that exosomes play an important role how stem cells exert their cellular functions.
Companies Commercializing Exosomes
Over the past few years, the following companies have emerged as specialists in exosome technologies. These exosome companies include:
Aegle Therapeutics is the first extracellular vesicle company to be cleared by the FDA to enter the clinical trials in humans. Aegle is using bone marrow- MSC derived extracellular vesicles to treat severe dermatological disorders.
Anjarium Biosciences is developing a Hybridosome™ technology to engineer extracellular vesicles (including exosomes) to act as smart carriers. The technology allows therapeutic and diagnostic cargoes to be added into the lumen, as well as modification of vesicle surface properties (i.e. targeting ligands).
Capricor Therapeutics has an exclusive worldwide license agreement with Cedars-Sinai Medical Center for IP related to the development of exosomes originating from cardiosphere-derived cells (CDCs) for regenerative medicine applications.
Codiak Biosciences‘ technology capitalizes on the unique properties of exosomes which have been shown to deliver nucleic acids, proteins, lipids, and small molecules to various cell types.
Creative Medical Technologies Holdings
Creative Medical Technologies Holdings has a patent application that covers the use of the company’s AmnioStem product as a production tool for the generation of exosomes to regenerate damaged brain tissue after a stroke.
EXOCEL BIO was founded in March 2020 to manufacture and sell MSC-derived exosomes, known as NEXGEN REGEN™.
Exopharm is Melbourne-based start-up that has a patented purification technology called LEAP that can make proprietary exomeres in large scale and at low cost. Exomeres are pharmaceutical-grade vesicles sized 40-200nm that are purified using Exopharm’s LEAP ligand technology.
Exosome Diagnostics launched the first instrument for exosomal protein (exoProtein) capture and analysis directly from any biofluid.
Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics.
Exosome Sciences is working to discover exosome-based biomarkers to diagnose and monitor Alzheimer’s disease, Chronic Traumatic Encephalopathy (
Exosomics Siena SpA
Exosomics Siena SpA developed an exosome-based liquid biopsy that functions as a non-invasive cancer diagnostic.
Exogenus Therapeutics (Exo-T) is a biotechnology company dedicated to pre-
An FDA registered tissue facility, Kimera Labs is developing amniotic treatments and pharmaceutical grade, exosome-based regenerative therapies.
Lonza announced May 2017 that it had acquired HansaBioMed Life Sciences, a supplier of technology and services for exosome research, and also invested in Exosomics, an Italian firm developing next-generation sequencing-based cancer tests.
ReNeuron is a clinical stage biotechnology company headquartered in the UK that is developing exosomes derived from its CTX neural stem cell line.
RoosterBio and Exopharm announced August 2017 that they will collaborate on a Stem Cell Exomere Program, aimed to bring high-grade therapeutic extracellular vesicles/exosomes derived from adult stem cells into clinical practice.
Exosome Companies On The Rise
In recent years, exosomes have been gaining momentum as a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients. Exosome companies are multiplying in number, with new market entrants popping up rapidly.
Do you know of other exosome companies that should be on this list? Share them in the comments below.
If you found this blog valuable, subscribe to BioInformant’s stem cell industry updates.
To learn more about this rapidly growing market area, view “The Market for Stem Cell Exosomes.”